Bristol-Myers Squibb shares slip as kidney cancer drug trial falls short of goal

...use of the drugs Opdivo and Yervoy showed that renal cell carcinoma patients responded better to the combination versus those taking the drug sunitinib, survival rates without progression of the disease did not reach statistical significance.08/16/2017
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news